BiotechTube

Qutenza exposure

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral Neuropathic Pain

Conditions

Peripheral Neuropathic Pain

Trial Timeline

Feb 1, 2012 → Aug 1, 2014

NCT ID
NCT01737294

About Qutenza exposure

Qutenza exposure is a pre-clinical stage product being developed by Astellas Pharma for Peripheral Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT01737294. Target conditions include Peripheral Neuropathic Pain.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT01737294Pre-clinicalCompleted

Competing Products

20 competing products in Peripheral Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
36
LY3857210 + PlaceboEli LillyPhase 2
52
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
85
YHD1119 + LyricaYuhanPhase 1
33
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
52
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Valemetostat TosylateDaiichi SankyoPhase 2
52
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
52
QutenzaAstellas PharmaPre-clinical
23
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
85
QUTENZAAstellas PharmaPhase 3
77
Qutenza + PregabalinAstellas PharmaApproved
85
Capsaicin 8% + PlaceboAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85